UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.  20549  FORM 10-QSB/A (Amendment No. 1)  |X| QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934  FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2006 or |   | TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934  Commission File Number 001-15975  REMEDENT, INC. (Exact name of small business issuer as specified in its charter)   NEVADA
        
        86-0837251(State or other jurisdiction of
incorporation or organization)
        
        (I.R.S.  EmployerIdentification Number)
   XAVIER DE COCKLAAN 42, 9831 DEURLE, BELGIUM
        N/A(Address of principal executive offices)
        (Zip code)
   011 32 9 321 70 80 (Issuer's telephone number)  Check whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YesxNo o  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o Nox  Number of shares of issuer's common stock outstanding as of November 14, 2006: 12,996,245  Transitional Small Business Disclosure Format (check one).  Yes o Nox  Documents incorporated by reference: None.     Explanatory Note  This Amendment No. 1 on Form 10-QSB/A (this Amendment) amends our Quarterly Report on Form 10-QSB for the three months ended September 30, 2006, originally filed on November 20, 2006 (the Original Filing). We are filing this Amendment solely to update Item 6 - Exhibits to include certain exhibits that were inadvertently omitted from Item 6  Exhibits in the Original Filing.  Except as described above, no other changes have been made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and we have not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Filing.  Part II  Other Information  Item 6.  Exhibits  The following documents are filed as part of this Amendment:  Exhibit No.  10.32
        Amendment to Line of Credit Agreement by and Between Remedent, N.V. and Fortis Bank dated September 1, 2006, subject to the General Terms and Conditions (1)
  31.1
        Certifications of the Chief Executive Officer Under Section 302 of the Sarbanes-Oxley Act
  31.2
        Certifications of Chief Financial Officer Under Section 302 of the Sarbanes-Oxley Act
  32.1
        Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act
  32.2
        Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act_____________________________________________
  (1)
        The General Terms and Conditions are incorporated by reference to Form 10-KSB/A2 filed with the SEC on June 11, 2007.
  2
    SIGNATURES  In accordance with the requirements of the Exchange Act the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.  REMEDENT, INC.
   Dated: June 8, 2007
        /s/ Robin List
 By:  Robin List
 Its: Chief Executive Officer (Principal
 Executive Officer) and Director
   Dated: June 8, 2007
        /s/ Philippe Van Acker
 By:  Philippe Van Acker
 Its: Chief Financial Officer (Principal
 Financial Officer and Principal
 Accounting Officer)
   3